Endava Faces Steep Market Discount Following Massive Q3 Earnings Loss

New York, Sunday, 24 May 2026.
Trading near $3.33 against an $8.56 fair value estimate, Endava faces severe market pessimism after a massive Q3 impairment charge triggered a net loss and sparked legal investigations.